Skip to content
Markets News
Earnings1 min read

Regeneron Revenue Jumps 36% as Key Drugs Post Gains

Makkler Newsroom
October 30, 2026 · Based on reporting by GlobeNewswire

The company reported higher quarterly revenue and earnings, expanded its Sanofi alliance, and raised parts of its 2026 financial outlook.

Key takeaways

  • Third-quarter revenue rose 36% to $5,116 million.
  • Non-GAAP earnings per share increased 70% to $20.07.
  • Regeneron received a $1 billion upfront payment under an expanded Sanofi collaboration.
  • The FDA approved Pasatru for adults with fibrodysplasia ossificans progressiva.

Regeneron reported third-quarter revenue of $5,116 million, up 36% from a year earlier, while non-GAAP earnings per share rose 70% to $20.07. GAAP earnings per share increased 35% to $18.45.

Shares traded at $911.53, up 11.33% from the previous close, as of Friday afternoon. Regeneron attributed the revenue increase to stronger commercial performance and higher Sanofi collaboration revenue.

The company said U.S. sales of EYLEA HD rose 62% to $699 million, while global Libtayo sales climbed 51% to $550 million. Dupixent global net sales, recorded by Sanofi, increased 35% to $6.5 billion.

Regeneron also expanded its antibody collaboration with Sanofi, adding four next-generation, long-acting antibodies. It received a $1 billion upfront payment, which it expects to recognize as collaboration revenue in the fourth quarter, and may receive up to $7 billion more in development, regulatory and sales milestones.

The company raised its 2026 research and development spending outlook and lowered its selling, general and administrative expense guidance. The FDA approved Pasatru in August to reduce new lesions and flare-ups in adults with fibrodysplasia ossificans progressiva.

Topics
REGNSANSanofiDupixentEYLEA HDLibtayo
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.